About Biolexis Therapeutics
Biolexis Therapeutics is a company based in Salt Lake City (United States) founded in 2021 by David J Bearss and Hariprasad Vankayalapati. Biolexis Therapeutics has raised $14.1 million across 5 funding rounds from investors including Clarke Capital Partners. Biolexis Therapeutics offers products and services including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors. Biolexis Therapeutics operates in a competitive market with competitors including Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.
- Headquarter Salt Lake City, United States
- Founders David J Bearss, Hariprasad Vankayalapati
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biolexis Therapeutics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.1 M (USD)
in 5 rounds
-
Latest Funding Round
$1.6 M (USD), Series A
May 20, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biolexis Therapeutics
Biolexis Therapeutics offers a comprehensive portfolio of products and services, including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors.
Targets GLP-1 for obesity treatment and reduces side effects.
Activates protein kinase for obesity and overall health benefits.
Inhibits pathways to address longevity and chronic diseases.
Develops inhibitors for metabolic and related health issues.
People of Biolexis Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Biolexis Therapeutics
Biolexis Therapeutics has successfully raised a total of $14.1M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $1.6 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biolexis Therapeutics
Biolexis Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Clarke Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment expertise is utilized by Clarke Capital Partners to grow businesses.
|
Locked | Locked | Locked |
Investor details for Biolexis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biolexis Therapeutics
Investment portfolio details for Biolexis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biolexis Therapeutics
Detailed financials for Biolexis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biolexis Therapeutics Comparisons
Peer comparison for Biolexis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biolexis Therapeutics
Biolexis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery services are offered by Medeloop as a CRO.
|
|
| Locked | Locked | Locked |
Specialized CRO with expertise in recombinant protein production and purification
|
|
| Locked | Locked | Locked |
Covalent medicines platform is advanced for drug discovery targeting proteins.
|
|
| Locked | Locked | Locked |
Customized AAV-based viral vectors for gene therapy are supplied.
|
|
| Locked | Locked | Locked |
Antibody-drug research and development services are provided.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to pharmaceutical and biotech clients.
|
Detailed competitors of Biolexis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biolexis Therapeutics
Complete news archive for Biolexis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biolexis Therapeutics
Biolexis Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Biolexis Therapeutics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Biolexis Therapeutics is a funded company, having raised a total of $14.1M across 5 funding rounds to date.
Biolexis Therapeutics was founded in 2021 and is based in Salt Lake City, United States. Operations are centered on contract research organization services within the biotechnology sector. Drug discovery efforts for small molecule therapeutics are emphasized, with support provided for early-stage development processes. Co-founders David J. Bearss and Hariprasad Vankayalapati lead the initiative focused on advancing therapeutic innovations.
Biolexis Therapeutics's top competitors include Medeloop, Pure Biologics and Centivax.
Biolexis Therapeutics offers Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors.
Biolexis Therapeutics has 1 investor. Key investors include Clarke Capital Partners.